The 4 Claim Categories That Trigger FTC Action on Longevity Brands

On a long enough timeline, every marketer becomes their own narrator.

The complaint isn't waiting for the wrong number. It's waiting for the wrong category. Most longevity founders read for disease claims and skip the other three. This post walks all four.

The Problem: You Audited One Claim Type. There Are Four.

Here's the pain. Your lawyer read your landing page and circled the words treats, cures, prevents. She told you to swap them for supports and promotes. You did. You felt safer.

Then last quarter a competitor in your category ran nearly the same copy as yours, plus an influencer post with the exact testimonial language your own ambassadors run, and the FTC filed a complaint. You read the docket. You couldn't tell which sentence killed them. That's the problem.

The FTC doesn't read one claim category. It reads several. The agency's "Health Products Compliance Guidance" (FTC, December 2022) ships more like a sentencing template than advice¹. The Guidance walks the categories agency staff use to read deceptive health claims. The four below hit hardest in longevity enforcement.

You're not loose with your language. You're loyal to a single rubric (the FDA's structure-function line) when the FTC reads you against three more rubrics in the same case. You patched the disease claim. The FTC reads three more.

The philosophical problem lifts founders out of bed at 3 a.m. The FTC publishes its enforcement complaints, and every complaint becomes a permanent public record on the agency website. Your retailer pulls it before the consent order ships. So does your insurance underwriter. So does the plaintiff's bar.

The Guide: I Read The Guidance And The Cases

I run Paper St Marketing. I read the FTC's December 2022 Health Products Compliance Guidance¹. I read the complaints behind the four enforcement actions I'll cite. Each one ships a different lesson.

Here's the structure. The FTC files under Section 5 of the FTC Act, which bars deceptive acts and practices. For a health claim, deceptive runs a specific test: a claim is deceptive when it lacks competent and reliable scientific evidence (CRSE) (FTC Guidance, 2022)¹. The Guidance walks several kinds of claim that draw CRSE scrutiny. The four kinds below run independent. A claim can pass one and fail another.

The failure mode here, the thing Charlie Munger would invert, is reading the disease line as the only line. Founders read the FDA's structure-function rule, swap the verbs, and feel safer. The FTC reads the FDA's rule too. The agency also examines your testimonials, your statistics, and the words clinically proven on your splash page. Disease verbs ship the easy patch. The harder substantiation patches sit in the other three categories.

A claim crosses one category and your lawyer flags it. A claim crosses two and the complaint reads as a pattern. A claim crosses three and your defense theory runs thin.

The Plan: Walk All Four Categories

Here's the play. Run each category against your live copy. The order runs from "fastest to read off the page" to "needs a records pull."

1. Disease/treatment claims (FTC Section 5 + FD&C Act). Read every sentence that names a disease or condition. The FTC and FDA run this lane together. The FDA reads the structure-function line. The FTC reads net impression. Net impression means a sentence the reader hears as a disease claim IS a disease claim, even when no disease word appears. In December 2020, the FTC ran Operation CBDeceit, hitting six CBD sellers for claims their products treat cancer, Alzheimer's, COVID, multiple sclerosis, and similar conditions (FTC press release, Dec 17, 2020)². Five of the six paid civil penalties from roughly $20,000 to $85,000 per case (FTC, 2020)². Why this matters: supports and promotes still cross when the surrounding marketing names the disease. Read your full funnel, not your splash page.

2. Establishment claims (FTC CRSE standard). Read every place you wrote clinically proven, studies show, scientifically validated, or any close cousin. The FTC reads establishment claims at the highest evidentiary bar. In the POM Wonderful matter, the FTC found the brand's heart-disease, prostate-cancer, and erectile-dysfunction claims for its juice were not backed by competent and reliable scientific evidence. The D.C. Circuit upheld the FTC's order in January 2015, requiring at least one randomized, controlled, human clinical trial for disease prevention or treatment claims (POM Wonderful v. FTC, 777 F.3d 478, D.C. Cir. 2015)³. The court struck the FTC's two-RCT requirement on First Amendment grounds³. Why this matters: a single in vitro study or a 20-subject open-label pilot doesn't back an establishment claim about a disease outcome. If you can't ship the RCT, drop the word clinically.

3. Performance/outcome claims (substantiation under Section 5). Read every number and every result line. Members lost 22 pounds in 30 days. Users reported a 47% reduction in joint pain. Extends healthspan by X years. Each one needs CRSE that maps to the literal claim. The Guidance reads that performance claims must run representative of the underlying population, not cherry-picked from the best responders (FTC Guidance, 2022)¹. Why this matters: the testimonials you ship read as performance claims unless the typical outcome reads near the testimonial. The 2023 Endorsement Guides update killed the results not typical workaround for non-representative testimonials (FTC Federal Register, July 26, 2023)⁴.

4. Endorsement/testimonial claims (Endorsement Guides, updated 2023). Read every influencer post, ambassador story, and testimonial on your site. The FTC filed the final amended Endorsement Guides on June 29, 2023, and the Guides took effect on Federal Register publication, July 26, 2023 (FTC, 16 CFR Part 255)⁴. The updated Guides expanded brand liability for endorser statements, required clear and conspicuous #ad disclosure, and eliminated results not typical disclaimers as a cure for non-representative testimonials. In March 2020, the FTC filed against Teami LLC, a detox tea brand, for unsubstantiated weight-loss claims and an influencer program without proper disclosure. The court entered a $15.2 million judgment, suspended to $1 million on inability to pay (FTC v. Teami, M.D. Fla., 2020)⁵. Why this matters: every ambassador post lives in your case file. Pull them and read each one as if you wrote it.

A note on order. Categories 1 and 4 read fastest off the page. Category 2 reads fastest by grep for clinically. Category 3 needs a records pull (do you ship the trial data the testimonial implies?). Run all four. The CRSE standard binds you, not your lawyer's swap-list.

The Stakes: What An FTC Complaint Actually Costs

Here's what the complaint ships. Like an FDA warning letter, it reads as a public document. The FTC posts it on ftc.gov the day it files (FTC, ftc.gov)⁶. The complaint is not the fine. The complaint is the trigger.

The cost shows up in four places. Your retailer reads the complaint and pauses your purchase orders pending response. Your insurance carrier reads it and raises your product liability premium at next renewal. A class-action firm reads it and files. Your payment processor reads it and reviews your account.

The Teami case ran a $15.2 million judgment, suspended to $1 million on inability to pay (FTC v. Teami, 2020)⁵. The retailer, insurance, and class-action cost the brand also paid never ships on the FTC docket.

The Call: Audit Before The FTC Does

Run the four-category audit this Saturday. Read your live page. Read your testimonials. Grep your site for clinically. Open your ambassador drive and pull three random posts. Score each line against the four categories above. If a line crosses, patch it before the complaint reads it. The fix runs faster than the docket.

I am Jack's broken heart.